Making life easy for differently-abled through inclusive, accessible spaces
The move aims to develop the country's first Purple Building Certification Scheme, a dedicated accessibility rating system for buildings. The scheme is envisioned as a core tool within that campaign to institutionalise accessibility across public spaces.
More than 50 leading national experts in accessibility, disability rights, architecture and urban planning will come together at the AMTZ campus on June 11 and 12 to deliberate and finalise the framework.
The certification is aimed at ensuring that public and private buildings across India are designed and operated in ways that are accessible for persons with disabilities, senior citizens, pregnant women, and all users with mobility and sensory needs.
The Purple Building Certification Scheme is being designed as a structured, scalable tool that will assess buildings based on universal design principles. By uniting the government, private sector, civil society and persons with disabilities, the scheme aims to build inclusive cities.
It will include detailed checklists, tiered ratings (basic to excellence), and measurable benchmarks covering entrances, ramps, signage, washrooms, elevators, pathways, and digital accessibility. 'Accessibility should not be seen as an exception, but as a foundation of every building in a truly inclusive nation. With the Purple Building Certification, AMTZ is proud to lead a national movement that redefines how India builds, ensuring dignity, safety, and equal access for all including Divyangjans,' shared Dr. Jitendra Sharma, managing director and founder CEO, AMTZ.
Three expert committees are meeting to build a national standard for accessibility. Once adopted, Purple Certification will serve as a voluntary yet widely recognised benchmark for schools, hospitals, shopping complexes, corporate offices, and even housing societies.
The MedTech zone is already a national partner in the ongoing Sugamya Delhi Abhiyan, a people-led campaign spearheaded by Inclusive Divyangjan Entrepreneurs Association (IDEA). Experts believe that such certification could be a game changer, filling the long-standing gap between progressive laws and real-world implementation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
5 days ago
- Business Standard
Execution risks, valuations likely to cap upside in Zydus Lifesciences
Zydus Lifesciences delivered a better-than-expected 2025-26 (FY26) April–June quarter (Q1), particularly on the top line. This, coupled with launches and the prospect of margin improvement, led some analysts to upgrade their outlook. While sentiment remains positive and the stock gained over 3 per cent in Wednesday's trade, brokerages are cautious due to margin pressures and premium valuations. The stock is up about 12 per cent from its May lows. Driven by its India and international businesses, the company recorded 6 per cent revenue growth in Q1FY26. While India sales rose 6 per cent, it was the international formulations arm that delivered the bigger lift, climbing 37 per cent on the back of consistent execution and growth across regions. The US market, which accounts for 48 per cent of sales, grew 2.9 per cent year-on-year (Y-o-Y) and was flat in constant currency terms. Sequential growth was 1.6 per cent. Motilal Oswal Research, which has raised its earnings estimates, notes that despite competition in products like generic versions of the cancer drug Revlimid and the anti-inflammatory drug Asacol, Zydus reported sequential gains in sales and a steady Y-o-Y performance at $372 million. This was largely supported by solid demand in its base portfolio, new launches, and stable business from the generic version of Myrbetriq, a treatment for overactive bladder. Alongside Myrbetriq, upcoming launches are expected to help the company sustain single-digit growth in the US, given the anticipated drop in Revlimid orders. While some new products are set to launch in FY26, most of the scale-up is expected in 2026-27 (FY27). The company said it has filed 15 of the 25 products in its pipeline, while Sitagliptin (Type 2 diabetes), which is already on the market, has seen early traction. In the domestic market, the formulation business posted 8 per cent Y-o-Y growth, while the consumer wellness segment rose 2 per cent. Branded formulations outpaced the broader market, growing 9 per cent, led by key brands and new products. The company has stepped up its focus on chronic therapies, with cardiology standing out in the quarter with 22.5 per cent growth. Chronic therapies now make up 43.7 per cent of the portfolio, up more than 420 basis points in three years, with the company retaining its lead in oncology. Most brokerages, however, remain cautious. Antique Stock Broking notes that the company is evolving into a diversified healthcare platform with exposure to MedTech, biologics contract development and manufacturing, and innovation-led therapies. While this shift could justify a rerating over time, analysts Gaurav Tinani and Vamsi Hota believe execution and visibility remain critical. 'FY27 poses a more challenging outlook, with potential revenue and margin headwinds arising from the loss of exclusivity in key high-margin products such as generic versions of Revlimid and Myrbetriq.' Higher research and development spending, increased depreciation, and interest costs after acquisitions could also weigh on earnings, prompting the brokerage to maintain a 'hold' rating. Given the risks to the US portfolio from mounting competition and ongoing litigation, analysts Tushar Manudhane and Eshita Jain of Motilal Oswal Research project an overall 5 per cent decline in operating and net profit from 2024-25 through FY27. They have a 'neutral' rating on the stock, with current valuations offering limited upside. While Zydus has invested in multiple long-term opportunities, earnings growth is expected to slow after FY26 due to the loss of exclusivity for generic versions of Revlimid and Myrbetriq, says JM Financial Research. At current valuations of 25x FY27 earnings per share, the stock trades at a 10 per cent premium to the largecap peer average, say analysts at the brokerage led by Amey Chalke. It has a 'hold' rating on the stock.
Economic Times
11-08-2025
- Economic Times
Lord's Mark Industries Ltd set to debut on BSE with plans for NSE entry and international growth
Synopsis Lord's Mark Industries Ltd is set to list on the Bombay Stock Exchange (BSE) following its merger approval, aiming to boost expansion and shareholder value through a share exchange program. This move has attracted international investor interest, particularly in its Medtech and renewable energy sectors. Spotlight Wire Lord's Mark Industries Ltd, an Indian conglomerate operating across healthcare, diagnostics, renewable energy, and advanced technology sectors, is preparing to enter the capital markets through a planned listing on the Bombay Stock Exchange (BSE). This strategic initiative underscores the company's vision to expand its footprint both domestically and public listing comes on the heels of the company's recent approval from the National Company Law Tribunal (NCLT) for its merger with Lord's Mark India Ltd (previously known as Kratos Energy and Infrastructure Ltd). This merger aims to enhance operational synergies, facilitate improved resource allocation, optimise management structures, and drive aggressive expansion into emerging business segments. Advantageous share exchange programme for stakeholdersUnder the merger framework, existing shareholders of Lord's Mark Industries Ltd will benefit from a share exchange ratio of 1:1.25. Each share owned in Lord's Mark Industries Ltd will be converted to 1.25 shares in the merged entity, Lord's Mark India Ltd. This attractive ratio demonstrates the company's dedication to maximising shareholder value while establishing a more robust and agile corporate structure. International investment interest and strategic alliances The BSE listing announcement has generated considerable attention from global investors, reflecting strong confidence in Lord's Mark Industries' diversified operations, market resilience, and progressive business strategies. The company has secured a substantial proposal for an international collaboration related to its Medtech product portfolio, a premier offering within the renewable energy division. This alliance is expected to enhance the company's global market penetration and strengthen its position as a leading force in the sustainable energy sector. Stock Exchange Strategy: BSE debut leading to NSE aspirationsThe BSE listing represents the initial phase of Lord's Mark Industries' comprehensive capital market strategy. Looking ahead, the company has outlined plans to secure a National Stock Exchange (NSE) listing within the coming six months. This multi-exchange approach is expected to improve stock liquidity, broaden the shareholder base, and increase visibility among domestic and international institutional investors. The NSE listing will also facilitate enhanced price discovery mechanisms and greater capital accessibility, essential elements for the company's ambitious growth objectives. For additional information, visit Disclaimer - The above content is non-editorial, and TIL hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.
Time of India
11-08-2025
- Time of India
Lord's Mark Industries Ltd set to debut on BSE with plans for NSE entry and international growth
Lord's Mark Industries Ltd, an Indian conglomerate operating across healthcare, diagnostics, renewable energy, and advanced technology sectors, is preparing to enter the capital markets through a planned listing on the Bombay Stock Exchange (BSE). This strategic initiative underscores the company's vision to expand its footprint both domestically and internationally. The public listing comes on the heels of the company's recent approval from the National Company Law Tribunal (NCLT) for its merger with Lord's Mark India Ltd (previously known as Kratos Energy and Infrastructure Ltd). This merger aims to enhance operational synergies, facilitate improved resource allocation, optimise management structures, and drive aggressive expansion into emerging business segments. Advantageous share exchange programme for stakeholders by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo Under the merger framework, existing shareholders of Lord's Mark Industries Ltd will benefit from a share exchange ratio of 1:1.25. Each share owned in Lord's Mark Industries Ltd will be converted to 1.25 shares in the merged entity, Lord's Mark India Ltd. This attractive ratio demonstrates the company's dedication to maximising shareholder value while establishing a more robust and agile corporate structure. International investment interest and strategic alliances The BSE listing announcement has generated considerable attention from global investors, reflecting strong confidence in Lord's Mark Industries' diversified operations, market resilience, and progressive business strategies. The company has secured a substantial proposal for an international collaboration related to its Medtech product portfolio, a premier offering within the renewable energy division. This alliance is expected to enhance the company's global market penetration and strengthen its position as a leading force in the sustainable energy sector. Live Events Stock Exchange Strategy: BSE debut leading to NSE aspirations The BSE listing represents the initial phase of Lord's Mark Industries' comprehensive capital market strategy. Looking ahead, the company has outlined plans to secure a National Stock Exchange (NSE) listing within the coming six months. This multi-exchange approach is expected to improve stock liquidity, broaden the shareholder base, and increase visibility among domestic and international institutional investors. The NSE listing will also facilitate enhanced price discovery mechanisms and greater capital accessibility, essential elements for the company's ambitious growth objectives. For additional information, visit Disclaimer - The above content is non-editorial, and TIL hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.
